Xenon Pharmaceuticals Inc.
XENE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -961.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -867.3% | – |
| EPS Diluted | -1.15 | -1.07 | -0.83 | -0.84 |
| % Growth | -7.5% | -28.9% | 1.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |